Synchron Raises $200 Million Series D
Synchron has secured $200 million in Series D funding to accelerate the development and commercialization of its brain-computer interface (BCI) technology.
Funding Purpose and Impact
The new investment will support the advancement of the Stentrode™ BCI platform, enhancing its commercial readiness. Additionally, it will enable expansion of Synchron's artificial intelligence and engineering teams based in New York and San Diego.
About the Stentrode™ Platform
The Stentrode™ Endovascular Electrode Array is at the center of Synchron’s innovative BCI technology.
Media Contact
Kimberly Ha — [email protected]
Synchron’s substantial funding marks a significant step towards making brain-computer interfaces widely accessible by boosting its platform's commercialization and technical capabilities.